Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease

Katharine A. Whartenby, Peter A. Calabresi, Erin McCadden, Bao Nguyen, David Kardian, Tianhong Wang, Claudio A. Mosse, Drew M. Pardoll, Donald SmallProceedings of the National Academy of Sciences 2005 · DOI

TL;DR

This paper explores a novel approach to treating autoimmune diseases by targeting dendritic cells (DCs), key players in initiating immune responses. By inhibiting the FLT3 receptor on DCs, the researchers found they could induce DC apoptosis, dampen T cell activation, and significantly improve symptoms in a mouse model of multiple sclerosis, suggesting a promising new therapeutic strategy.

What Problem Does This Paper Address?

Autoimmune diseases, where the immune system mistakenly attacks the body's own tissues, are often treated by broadly suppressing T cells. While this can be effective, it comes with significant side effects and can leave patients vulnerable to infections. This paper addresses the need for more targeted immunotherapies by investigating the role of antigen-presenting cells (APCs), specifically dendritic cells (DCs), in the development of autoimmune diseases. DCs are crucial for initiating T cell responses, and their dysregulation can lead to autoreactivity. The authors hypothesize that by targeting DCs, they can achieve a more specific and potentially safer way to control autoimmune inflammation.

Methods

The researchers utilized a combination of in vitro and in vivo experiments.

  • In vitro studies:
    • DC generation: Bone marrow (BM) cells from mice and peripheral blood mononuclear cells from humans were cultured with growth factors (GM-CSF, IL-4, and sometimes FLT3 ligand) to differentiate into DCs.
  • FLT3 inhibition: A small-molecule tyrosine kinase inhibitor (TKI) called CEP-701, specifically targeting FLT3, was used to treat DCs.
  • Western Blotting: Used to confirm FLT3 expression on mature DCs and assess the inhibition of FLT3 phosphorylation by CEP-701.
  • Flow Cytometry (FACS): Employed to measure DC apoptosis (using Annexin V staining) and assess DC maturation markers (MHC class II expression).
  • T cell proliferation assays: Irradiated DCs treated with CEP-701 were co-cultured with T cells to measure T cell activation and cytokine production (IFN-γ, TNF-α). They also tested if CEP-701 directly affected T cell function by stimulating T cells on anti-CD3-coated plates.
  • In vivo studies:
    • Mouse models:
      • Autoreactive T cell expansion model: Transgenic mice (HA137) were treated with CEP-701 before adoptive transfer of HA-specific T cells to assess the impact on T cell expansion.
  • Experimental Autoimmune Encephalomyelitis (EAE) model: This is a standard model for multiple sclerosis. Mice were induced with EAE and then treated with CEP-701 either prophylactically or after disease onset to evaluate its therapeutic effect on disease severity and pathology (myelin loss).
  • Infectious challenge model: Mice treated with CEP-701 were challenged with Listeria monocytogenes to assess potential broad immunosuppression.
  • FACS analysis: Used to analyze immune cell populations (DCs, NK cells, T cells, B cells) in spleens and lymph nodes of treated mice.
  • Histopathology: Spinal cord sections from EAE mice were stained to assess myelin damage.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • FLT3 is crucial for DC survival: Beyond its known role in DC progenitor development, FLT3 signaling is essential for maintaining the survival of mature DCs. Inhibiting it leads to apoptosis.
  • Targeting DCs offers a novel therapeutic avenue: Instead of broadly suppressing T cells, targeting DCs, the initiators of immune responses, presents a more specific strategy for autoimmune disease treatment.
  • FLT3 inhibition is effective after disease onset: A significant finding is that CEP-701 improved established EAE, suggesting it can be used therapeutically even when the autoimmune process is already underway, not just preventatively.
  • Targeted immunosuppression: FLT3 inhibition appears to selectively reduce DC and NK cell populations, sparing T and B cells, which hints at a more controlled immunosuppressive effect compared to traditional methods.
  • DC inhibitors could bypass the need for autoantigen identification: This approach offers a potential advantage in treating autoimmune diseases where identifying the specific autoantigen is challenging.

Key Results

  • FLT3 inhibition induces DC apoptosis: CEP-701 treatment led to a dose-dependent increase in apoptosis in both mouse and human mature DCs.
  • Reduced T cell stimulation: DCs treated with CEP-701 showed significantly decreased ability to stimulate T cell proliferation and cytokine production in vitro.
  • In vivo DC reduction: Treatment of mice with CEP-701 resulted in a decrease in DC and NK cell populations in spleens and lymph nodes, without affecting T or B cells.
  • Suppression of autoreactive T cell expansion: In a transgenic model, CEP-701 treatment significantly reduced the expansion of antigen-specific T cells.
  • Amelioration of established EAE: Mice with established EAE treated with CEP-701 showed significantly reduced disease severity and demyelination compared to controls.
  • No gross immunosuppression: CEP-701 treatment did not impair the ability of mice to survive an infectious challenge (L. monocytogenes), suggesting the immunosuppression is not overly broad or toxic.

Limitations and Future Work

  • Transgenic T cell receptor limitation: The authors acknowledge that using a transgenic T cell receptor in one model has limitations for fully mimicking natural autoimmune responses.
  • Need for broader immunosuppression studies: While the L. monocytogenes challenge showed no gross immunosuppression, further studies are needed to comprehensively evaluate effects on immunity and different types of immune challenges.
  • Clinical translation: The authors emphasize that additional comprehensive studies are necessary before clinical use for autoimmune diseases.
  • Potential for DC-targeted therapies: The paper suggests that DC-targeted therapies could be beneficial for blocking epitope spreading in chronic autoimmune settings or limiting exacerbations.
  • Oral availability and outpatient administration: The authors highlight that FLT3 inhibitors, already developed for leukemia, are orally available and suitable for outpatient use, making them attractive for chronic autoimmune disease management.

Summary updated

Abstract

Autoimmune diseases often result from inappropriate or unregulated activation of autoreactive T cells. Traditional approaches to treatment of autoimmune diseases through immunosuppression have focused on direct inhibition of T cells. In the present study, we examined the targeted inhibition of antigen-presenting cells as a means to downregulate immune responses and treat autoimmune disease. Dendritic cells (DCs) are the central antigen-presenting cells for the initiation of T cell responses, including autoreactive ones. A large portion of DCs are derived from hematopoietic progenitors that express FLT3 receptor (CD135), and stimulation of the receptor via FLT3 ligand either in vivo or in vitro is known to drive expansion and differentiation of these progenitors toward a DC phenotype. We hypothesized that inhibition of FLT3 signaling would thus produce an inhibition of DC-induced stimulation of T cells, thereby inhibiting autoimmune responses. To this end, we used small-molecule tyrosine kinase inhibitors targeted against FLT3 and examined the effects on DCs and their role in the promulgation of autoimmune disease. Results of our studies show that inhibition of FLT3 signaling induces apoptosis in both mouse and human DCs, and thus is a potential target for immune suppression. Furthermore, targeted inhibition of FLT3 significantly improved the course of established disease in a model for multiple sclerosis, experimental autoimmune encephalomyelitis, suggesting a potential avenue for treating autoimmune disease.
BibTeX
@inproceedings{whartenby2005inhibition,
  author = {Katharine A. Whartenby and Peter A. Calabresi and Erin McCadden and Bao Nguyen and David Kardian and Tianhong Wang and Claudio A. Mosse and Drew M. Pardoll and Donald Small},
  title = {{Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {2005},
  doi = {10.1073/pnas.0506088102},
}
Figure